(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of 3.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Akebia Therapeutics's revenue in 2024 is $194,623,000.On average, 2 Wall Street analysts forecast AKBA's revenue for 2024 to be $40,100,024,969, with the lowest AKBA revenue forecast at $39,385,018,650, and the highest AKBA revenue forecast at $40,815,031,289. On average, 2 Wall Street analysts forecast AKBA's revenue for 2025 to be $32,856,791,116, with the lowest AKBA revenue forecast at $25,937,037,427, and the highest AKBA revenue forecast at $39,776,544,805.
In 2026, AKBA is forecast to generate $48,997,299,796 in revenue, with the lowest revenue forecast at $47,563,099,712 and the highest revenue forecast at $50,431,499,879.